drugset
Drugs / BG505 SOSIP GT1.1 gp140
last change Aug 2023 re-read 3 minutes ago

BG505 SOSIP GT1.1 gp140

Vaccine

Developed for
HIV infectious disease
Investigated by
Amsterdam UMC, location VUmc · George Washington University · GlaxoSmithKline · International AIDS Vaccine Initiative · Rockefeller University

Trials 1

today NCT04224701 · Ph 1
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04224701 Aug 2020 → Jul 2023 HIV infectious disease International AIDS Vaccine Initiative Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BG505 SOSIP GT1.1 gp140 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04224701 ↗
Modality Vaccine “HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine” NCT04224701 ↗
Route Intramuscular “will be administered IM” NCT04224701 ↗